Aurobindo Pharma Limited — China registrations and re-registration filing lines
28 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest filing line: 2027-03-19.
| Approval number | Product | Certificate expires | Filing line (Art. 82) |
|---|---|---|---|
| 国药准字HJ20220073 | Levetiracetam Tablets 左乙拉西坦片 | 2027-09-19 | 2027-03-19 |
| 国药准字HJ20220074 | Levetiracetam Tablets 左乙拉西坦片 | 2027-09-19 | 2027-03-19 |
| 国药准字HJ20220075 | Levetiracetam Tablets 左乙拉西坦片 | 2027-09-19 | 2027-03-19 |
| 国药准字HJ20220079 | Mirtazapine Tablets 米氮平片 | 2027-10-10 | 2027-04-10 |
| 国药准字HJ20220080 | Mirtazapine Tablets 米氮平片 | 2027-10-10 | 2027-04-10 |
| 国药准字HJ20220095 | Aripiprazole Tablets 阿立哌唑片 | 2027-12-19 | 2027-06-19 |
| 国药准字HJ20220096 | Aripiprazole Tablets 阿立哌唑片 | 2027-12-19 | 2027-06-19 |
| 国药准字HJ20230039 | Amlodipine Besilate Tablets 苯磺酸氨氯地平片 | 2028-04-16 | 2027-10-16 |
| 国药准字HJ20230040 | Amlodipine Besilate Tablets 苯磺酸氨氯地平片 | 2028-04-16 | 2027-10-16 |
| 国药准字HJ20230069 | Finasteride Tablets 非那雄胺片 | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20230070 | Finasteride Tablets 非那雄胺片 | 2028-06-06 | 2027-12-06 |
| 国药准字HJ20230099 | Olmesartan Medoxomil and Amlodipine Besylate Tablets 奥美沙坦酯氨氯地平片 | 2028-08-07 | 2028-02-07 |
| 国药准字HJ20230100 | Olmesartan Medoxomil and Amlodipine Besylate Tablets 奥美沙坦酯氨氯地平片 | 2028-08-07 | 2028-02-07 |
| 国药准字HJ20230101 | Olmesartan Medoxomil and Amlodipine Besylate Tablets 奥美沙坦酯氨氯地平片 | 2028-08-07 | 2028-02-07 |
| 国药准字HJ20230121 | Valganciclovir Hydrochloride Tablets 盐酸缬更昔洛韦片 | 2028-10-23 | 2028-04-23 |
| 国药准字HJ20230122 | Sevelamer Carbonate Tablets 碳酸司维拉姆片 | 2028-10-26 | 2028-04-26 |
| 国药准字HJ20230141 | Fampridine Sustained-release Tablets 氨吡啶缓释片 | 2028-12-04 | 2028-06-04 |
| 国药准字HJ20230148 | Sertraline Hydrochloride Tablets 盐酸舍曲林片 | 2028-12-28 | 2028-06-28 |
| 国药准字HJ20240103 | Tadalafil Tablets 他达拉非片 | 2029-10-08 | 2029-04-08 |
| 国药准字HJ20240104 | Tadalafil Tablets 他达拉非片 | 2029-10-08 | 2029-04-08 |
| 国药准字HJ20240105 | Tadalafil Tablets 他达拉非片 | 2029-10-08 | 2029-04-08 |
| 国药准字HJ20250080 | Atazanavir Sulfate Capsules 硫酸阿扎那韦胶囊 | 2030-06-29 | 2029-12-29 |
| 国药准字HJ20250081 | Atazanavir Sulfate Capsules 硫酸阿扎那韦胶囊 | 2030-06-29 | 2029-12-29 |
| 国药准字HJ20250085 | Teriflunomide Tablets 特立氟胺片 | 2030-07-21 | 2030-01-21 |
| 国药准字HJ20250086 | Teriflunomide Tablets 特立氟胺片 | 2030-07-21 | 2030-01-21 |
| 国药准字HJ20200063 | Pantoprazole Sodium Enteric-Coated Tablets 泮托拉唑钠肠溶片 | 2030-11-13 | 2030-05-13 |
| 国药准字HJ20200064 | Pantoprazole Sodium Enteric-Coated Tablets 泮托拉唑钠肠溶片 | 2030-11-13 | 2030-05-13 |
| 国药准字HJ20250135 | Mesalazine Enteric-coated Sustained-release Capsules 美沙拉秦肠溶缓释胶囊 | 2030-11-24 | 2030-05-24 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.